Şeyma Sönmez Şahin
Şeyma Sönmez Şahin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Elif Karatoprak
İstanbul Medeniyet Üniversitesi Göztepe Prof Dr Süleyman Yalçın Şehir Hastanesi
5 shared publications - Mehmetcan Sezer
Department of Pediatric Neurology, Göztepe Prof. Dr. Süleyman Yalçın City Hospital, Istanbul, Türkiye
2 shared publications - Suleyman Cakiroglu
Altınbaş University, School of Medicine, Child and Adolescent Psychiatry, Istanbul, Türkiye
2 shared publications - Ahmet Mutlu
Department of Otorhinolaryngology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Türkiye
1 shared publication - Ahmet Sait Dilbirligi
Goztepe Prof. Dr. Suleyman Yalcın City Hospital, Clinic of Pediatrics, Istanbul, Türkiye
1 shared publication Akın İŞCAN
1 shared publication
Latest Publications
- 26 October 2026
- Published by Bezmialem Vakif University in Bezmialem Science
Measurement of Irisin, Adiponectin, and Leptin Levels in Patients with Idiopathic Epilepsy
Measurement of Irisin, Adiponectin, and Leptin Levels in Patients with Idiopathic Epilepsy - Bezmialem Science
- 26 October 2026
- Published by Bezmialem Vakif University in Bezmialem Science
Measurement of Irisin, Adiponectin, and Leptin Levels in Patients with Idiopathic Epilepsy
Measurement of Irisin, Adiponectin, and Leptin Levels in Patients with Idiopathic Epilepsy - Bezmialem Science
- Open Access
- 29 September 2026
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 31 (3) , 408-413
Febril/afebril nöbet öyküsü olan dikkat eksikliği ve hiperaktivite bozukluğu tanılı çocuklarda stimülan tedavi: Çocuk psikiyatristlerinin klinik deneyim ve yaklaşımları
Amaç: Bu çalışmanın amacı, febril veya afebril nöbet öyküsü bulunan dikkat eksikliği ve hiperaktivite bozukluğu (DEHB) tanılı çocuklarda stimülan tedavi kullanımına ilişkin çocuk psikiyatristlerinin klinik deneyim ve yaklaşımlarını değerlendirmektir. Ayrıca klinisyenlerin tedaviye yönelik güven düzeyleri ile mesleki deneyim ve klinik tercihler arasındaki ilişkilerin incelenmesi hedeflenmiştir.Yöntemler: Bu kesitsel çalışma, çevrim içi anket yöntemiyle çocuk ve ergen psikiyatristlerine uygulanmıştır. Anket formunda katılımcıların mesleki deneyimleri, nöbet öyküsü bulunan DEHB hastalarına yaklaşımları, stimülan tedavi tercihleri ve tedaviye yönelik güven düzeyleri sorgulanmıştır. Veriler tanımlayıcı istatistikler kullanılarak özetlenmiş, gruplar arası karşılaştırmalarda uygun parametrik olmayan testler uygulanmış ve değişkenler arasındaki ilişkiler korelasyon analizleri ile değerlendirilmiştir.Bulgular: Çalışmaya toplam 137 çocuk psikiyatristi katılmıştır. Katılımcıların %52,6’sı (n=72) mesleki yaşamlarında stimülan tedavisi sırasında nöbet geçirdiğini düşündükleri en az bir hastayla karşılaştıklarını bildirdi. Buna karşın, klinisyenlerin büyük çoğunluğu nöbet öyküsü olan DEHB hastalarında doğrudan stimülan tedavisine başlamak yerine öncelikle çocuk nörolojisi değerlendirmesi sonrasında tedaviye karar vermeyi tercih etmiştir. Stimülan tedavisi sırasında nöbet gözlemleme deneyimi ile tedavi tercihi arasında anlamlı ilişki saptanmamıştır. Mesleki deneyim süresi arttıkça stimülan tedavisine başlama konusundaki güven düzeyinin anlamlı olarak arttığı bulunmuştur.Sonuç: Nöbet öyküsü bulunan DEHB hastalarında stimülan tedavisine yönelik klinik yaklaşımlar heterojen olup, klinisyenler literatürdeki güven verici bulgulara rağmen temkinli bir yaklaşım sergilemektedir. Klinik deneyim, tedaviye yönelik güven düzeyini etkileyen önemli bir faktör olarak görünmektedir. Bu bulgular, nöbet öyküsü olan DEHB hastalarında tedavi kararlarının bireyselleştirilmesi gerektiğini ve disiplinlerarası iş birliğinin önemini vurgulamaktadır.
- 29 September 2026
- Published by Anadolu Klinigi Tip Bilimleri Dergisi in Anadolu Kliniği Tıp Bilimleri Dergisi
- Vol. 31 (3) , 408-413
Open AccessFebril/afebril nöbet öyküsü olan dikkat eksikliği ve hiperaktivite bozukluğu tanılı çocuklarda stimülan tedavi: Çocuk psikiyatristlerinin klinik deneyim ve yaklaşımları
Amaç: Bu çalışmanın amacı, febril veya afebril nöbet öyküsü bulunan dikkat eksikliği ve hiperaktivite bozukluğu (DEHB) tanılı çocuklarda stimülan tedavi kullanımına ilişkin çocuk psikiyatristlerinin klinik deneyim ve yaklaşımlarını değerlendirmektir. Ayrıca klinisyenlerin tedaviye yönelik güven düzeyleri ile mesleki deneyim ve klinik tercihler arasındaki ilişkilerin incelenmesi hedeflenmiştir.Yöntemler: Bu kesitsel çalışma, çevrim içi anket yöntemiyle çocuk ve ergen psikiyatristlerine uygulanmıştır. Anket formunda katılımcıların mesleki deneyimleri, nöbet öyküsü bulunan DEHB hastalarına yaklaşımları, stimülan tedavi tercihleri ve tedaviye yönelik güven düzeyleri sorgulanmıştır. Veriler tanımlayıcı istatistikler kullanılarak özetlenmiş, gruplar arası karşılaştırmalarda uygun parametrik olmayan testler uygulanmış ve değişkenler arasındaki ilişkiler korelasyon analizleri ile değerlendirilmiştir.Bulgular: Çalışmaya toplam 137 çocuk psikiyatristi katılmıştır. Katılımcıların %52,6’sı (n=72) mesleki yaşamlarında stimülan tedavisi sırasında nöbet geçirdiğini düşündükleri en az bir hastayla karşılaştıklarını bildirdi. Buna karşın, klinisyenlerin büyük çoğunluğu nöbet öyküsü olan DEHB hastalarında doğrudan stimülan tedavisine başlamak yerine öncelikle çocuk nörolojisi değerlendirmesi sonrasında tedaviye karar vermeyi tercih etmiştir. Stimülan tedavisi sırasında nöbet gözlemleme deneyimi ile tedavi tercihi arasında anlamlı ilişki saptanmamıştır. Mesleki deneyim süresi arttıkça stimülan tedavisine başlama konusundaki güven düzeyinin anlamlı olarak arttığı bulunmuştur.Sonuç: Nöbet öyküsü bulunan DEHB hastalarında stimülan tedavisine yönelik klinik yaklaşımlar heterojen olup, klinisyenler literatürdeki güven verici bulgulara rağmen temkinli bir yaklaşım sergilemektedir. Klinik deneyim, tedaviye yönelik güven düzeyini etkileyen önemli bir faktör olarak görünmektedir. Bu bulgular, nöbet öyküsü olan DEHB hastalarında tedavi kararlarının bireyselleştirilmesi gerektiğini ve disiplinlerarası iş birliğinin önemini vurgulamaktadır.
- 26 August 2026
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 48 (5) , 939-949
Rituximab-Associated Hypersensitivity Reactions in Pediatric Patients: A Real-World Analysis of Risk Profile and Desensitization Outcomes
Data regarding the incidence, clinical phenotype, and risk factors of hypersensitivity reactions (HSRs) associated with rituximab in pediatric populations remain limited. This study aimed to evaluate the frequency, clinical phenotype, severity, timing, and management outcomes of rituximab-associated HSRs and to investigate the factors for HSR development in children. This single-center retrospective cohort study included all patients aged 0–18 years who received rituximab between March 2019 and April 2026. Demographic characteristics, atopic comorbidities, concomitant immunosuppressive therapies, pre-infusion laboratory parameters, and HSR details were recorded. Reactions were classified according to Brown’s anaphylaxis grading system and phenotyped as Type I, cytokine release syndrome (CRS), or infusion-related reaction (IRR). A total of 30 patients (56.7% female; median age 12.6 years) received 129 rituximab infusions. The per-patient HSR rate was 13.3% (n=4), and the per-infusion rate was 3.1%. Two patients experienced Type I reactions (anaphylaxis), one had CRS, and one had an IRR. All HSRs occurred within the first two treatment courses, with a significantly lower median dose number in the HSR group (2 vs. 4; p=0.044). No demographic, clinical, or laboratory parameter was significantly associated with HSR development. Rapid drug desensitization (RDD) was successfully performed in three patients (11 procedures), enabling uninterrupted treatment continuation. Immediate HSRs to rituximab occur at a notable frequency in pediatric patients, predominantly during early treatment courses. RDD under pediatric allergy guidance allows safe treatment continuation even in children with a history of anaphylaxis. These findings underscore the importance of enhanced clinical vigilance during initial infusions and the integration of a multidisciplinary risk management approach.
- 26 August 2026
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 48 (5) , 939-949
Rituximab-Associated Hypersensitivity Reactions in Pediatric Patients: A Real-World Analysis of Risk Profile and Desensitization Outcomes
Data regarding the incidence, clinical phenotype, and risk factors of hypersensitivity reactions (HSRs) associated with rituximab in pediatric populations remain limited. This study aimed to evaluate the frequency, clinical phenotype, severity, timing, and management outcomes of rituximab-associated HSRs and to investigate the factors for HSR development in children. This single-center retrospective cohort study included all patients aged 0–18 years who received rituximab between March 2019 and April 2026. Demographic characteristics, atopic comorbidities, concomitant immunosuppressive therapies, pre-infusion laboratory parameters, and HSR details were recorded. Reactions were classified according to Brown’s anaphylaxis grading system and phenotyped as Type I, cytokine release syndrome (CRS), or infusion-related reaction (IRR). A total of 30 patients (56.7% female; median age 12.6 years) received 129 rituximab infusions. The per-patient HSR rate was 13.3% (n=4), and the per-infusion rate was 3.1%. Two patients experienced Type I reactions (anaphylaxis), one had CRS, and one had an IRR. All HSRs occurred within the first two treatment courses, with a significantly lower median dose number in the HSR group (2 vs. 4; p=0.044). No demographic, clinical, or laboratory parameter was significantly associated with HSR development. Rapid drug desensitization (RDD) was successfully performed in three patients (11 procedures), enabling uninterrupted treatment continuation. Immediate HSRs to rituximab occur at a notable frequency in pediatric patients, predominantly during early treatment courses. RDD under pediatric allergy guidance allows safe treatment continuation even in children with a history of anaphylaxis. These findings underscore the importance of enhanced clinical vigilance during initial infusions and the integration of a multidisciplinary risk management approach.
- 25 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 175-180
Retinal neuronal layers in children with idiopathic generalized epilepsy: effects of epilepsy and long-term valproate use
- 25 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 175-180
Retinal neuronal layers in children with idiopathic generalized epilepsy: effects of epilepsy and long-term valproate use
- Open Access
- 13 July 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (8) , 727-735
Molecular Analysis of SCN1A Gene Variants Associated with Dravet Syndrome: Implications for Diagnosis and Management
Objective: SCN1A variants are the primary genetic cause of Dravet syndrome (DS), a severe developmental and epileptic encephalopathy characterized by early-onset prolonged seizures and progressive neurodevelopmental impairment. Early molecular diagnosis may influence treatment decisions and clinical outcomes. To characterize the molecular spectrum of SCN1A variants and describe the associated clinical and therapeutic features in children with suspected DS. Methods: This retrospective study included children evaluated between 2018 and 2020 with clinical suspicion of DS or febrile seizures with epilepsy who were referred for SCN1A genetic testing. Next-generation sequencing was used to detect sequence variants, complemented by multiplex ligation-dependent probe amplification for copy number analysis. A total of 60 patients were screened, and 18 patients carrying pathogenic or likely pathogenic SCN1A variants and fulfilling clinical criteria for DS were included. Results: Eighteen patients were identified with heterozygous pathogenic or likely pathogenic SCN1A variants, including 6 novel variants. Segregation analysis demonstrated that all 15 tested patients had de novo variants. Seizure onset ranged from 2.5 to 8 months, predominantly before 6 months of age. Several patients were exposed to sodium channel–blocking agents prior to molecular confirmation, with seizure aggravation and subsequent treatment modification. All patients required multiple anti-seizure medications and showed varying degrees of neurodevelopmental impairment. Conclusion: SCN1A-confirmed DS is associated with substantial seizure burden and neurodevelopmental morbidity. Delayed molecular diagnosis may lead to inappropriate treatment exposure and seizure worsening. Early genetic testing in infants with early-onset seizures may improve treatment selection and clinical outcomes.
- 13 July 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (8) , 727-735
Open AccessMolecular Analysis of SCN1A Gene Variants Associated with Dravet Syndrome: Implications for Diagnosis and Management
Objective: SCN1A variants are the primary genetic cause of Dravet syndrome (DS), a severe developmental and epileptic encephalopathy characterized by early-onset prolonged seizures and progressive neurodevelopmental impairment. Early molecular diagnosis may influence treatment decisions and clinical outcomes. To characterize the molecular spectrum of SCN1A variants and describe the associated clinical and therapeutic features in children with suspected DS. Methods: This retrospective study included children evaluated between 2018 and 2020 with clinical suspicion of DS or febrile seizures with epilepsy who were referred for SCN1A genetic testing. Next-generation sequencing was used to detect sequence variants, complemented by multiplex ligation-dependent probe amplification for copy number analysis. A total of 60 patients were screened, and 18 patients carrying pathogenic or likely pathogenic SCN1A variants and fulfilling clinical criteria for DS were included. Results: Eighteen patients were identified with heterozygous pathogenic or likely pathogenic SCN1A variants, including 6 novel variants. Segregation analysis demonstrated that all 15 tested patients had de novo variants. Seizure onset ranged from 2.5 to 8 months, predominantly before 6 months of age. Several patients were exposed to sodium channel–blocking agents prior to molecular confirmation, with seizure aggravation and subsequent treatment modification. All patients required multiple anti-seizure medications and showed varying degrees of neurodevelopmental impairment. Conclusion: SCN1A-confirmed DS is associated with substantial seizure burden and neurodevelopmental morbidity. Delayed molecular diagnosis may lead to inappropriate treatment exposure and seizure worsening. Early genetic testing in infants with early-onset seizures may improve treatment selection and clinical outcomes.
- Open Access
- 23 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Pediatric Migraine Disability Assessment (PedMIDAS): translation into Turkish and cross-cultural adaptation
The Pediatric Migraine Disability Assessment (PedMIDAS) questionnaire is widely used to evaluate migraine-related disability in children and adolescents. The aim of this study was to assess the validity and test-retest reliability of the Turkish version of the PedMIDAS. The PedMIDAS was translated into Turkish using a forward-backward translation procedure. A total of 60 children and adolescents diagnosed with migraine participated in this cross-sectional study. Data collection was conducted in two sessions separated by 15 days. During the first session, sociodemographic information and migraine characteristics, including attack frequency, duration, and pain severity assessed by the visual analogue scale (VAS), were recorded. Participants also completed the Turkish PedMIDAS and the Child Self-Report form of the Pediatric Quality of Life Inventory™ 4.0 (PedsQL™) to evaluate convergent validity. Fifteen days later, the participants completed the Turkish PedMIDAS again to assess test-retest reliability. The Turkish version of the PedMIDAS demonstrated acceptable internal consistency (α = 0.74) and strong test-retest reliability (r = 0.92). PedMIDAS scores were significantly associated with migraine clinical characteristics and quality-of-life measures. The Turkish version of the PedMIDAS is a valid and reliable instrument for assessing migraine-related disability in children and adolescents.
- 23 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessPediatric Migraine Disability Assessment (PedMIDAS): translation into Turkish and cross-cultural adaptation
The Pediatric Migraine Disability Assessment (PedMIDAS) questionnaire is widely used to evaluate migraine-related disability in children and adolescents. The aim of this study was to assess the validity and test-retest reliability of the Turkish version of the PedMIDAS. The PedMIDAS was translated into Turkish using a forward-backward translation procedure. A total of 60 children and adolescents diagnosed with migraine participated in this cross-sectional study. Data collection was conducted in two sessions separated by 15 days. During the first session, sociodemographic information and migraine characteristics, including attack frequency, duration, and pain severity assessed by the visual analogue scale (VAS), were recorded. Participants also completed the Turkish PedMIDAS and the Child Self-Report form of the Pediatric Quality of Life Inventory™ 4.0 (PedsQL™) to evaluate convergent validity. Fifteen days later, the participants completed the Turkish PedMIDAS again to assess test-retest reliability. The Turkish version of the PedMIDAS demonstrated acceptable internal consistency (α = 0.74) and strong test-retest reliability (r = 0.92). PedMIDAS scores were significantly associated with migraine clinical characteristics and quality-of-life measures. The Turkish version of the PedMIDAS is a valid and reliable instrument for assessing migraine-related disability in children and adolescents.
- Open Access
- 27 March 2026
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 41 (1) , 76-86
Retrospective Assessment of Clinical and Laboratory Features in Pediatric Neurology Patients Presenting with Vertigo
Retrospective Assessment of Clinical and Laboratory Features in Pediatric Neurology Patients Presenting with Vertigo - Medeniyet Medical Journal
- 27 March 2026
- Published by Galenos Yayinevi in Medeniyet Medical Journal
- Vol. 41 (1) , 76-86
Open AccessRetrospective Assessment of Clinical and Laboratory Features in Pediatric Neurology Patients Presenting with Vertigo
Retrospective Assessment of Clinical and Laboratory Features in Pediatric Neurology Patients Presenting with Vertigo - Medeniyet Medical Journal
- Open Access
- 16 February 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Radiology and Imaging
Volumetric Brain Differences in Premature Children with Cerebral Palsy: A VolBrain-Based Magnetic Resonance Imaging Analysis
This study aims to compare volumetric magnetic resonance imaging (MRI) measurements between premature children with cerebral palsy (CP) and healthy controls, and to evaluate the relationship between volumetric data and clinical findings. This retrospective study included 53 premature CP patients (group 1) and 53 age- and sex-matched healthy controls (group 2). Brain volume measurements were obtained using the VolBrain program based on 3D T1-weighted MRI images. The mean ages at MRI acquisition were 4.32 years for group 1 and 4.73 years for group 2. Common MRI abnormalities in group 1 included periventricular leukomalacia (68%), periventricular and intraventricular hemorrhage sequelae (15%), and lateral ventriculomegaly (22%). Volumes of total cerebral tissue, white and gray matter, cerebellum, cerebellar gray matter, globus pallidus, and corpus callosum were significantly reduced in group 1 compared with group 2. Positive correlations were found between total cerebral white matter and cerebellar volumes with motor function scores in CP patients. Volumetric neuroimaging reveals more extensive and complex brain involvement in premature children with CP than previously assumed. VolBrain may offer a practical and objective method for monitoring disease progression in clinical settings.
- 16 February 2026
- Published by Georg Thieme Verlag KG in Indian Journal of Radiology and Imaging
Open AccessVolumetric Brain Differences in Premature Children with Cerebral Palsy: A VolBrain-Based Magnetic Resonance Imaging Analysis
This study aims to compare volumetric magnetic resonance imaging (MRI) measurements between premature children with cerebral palsy (CP) and healthy controls, and to evaluate the relationship between volumetric data and clinical findings. This retrospective study included 53 premature CP patients (group 1) and 53 age- and sex-matched healthy controls (group 2). Brain volume measurements were obtained using the VolBrain program based on 3D T1-weighted MRI images. The mean ages at MRI acquisition were 4.32 years for group 1 and 4.73 years for group 2. Common MRI abnormalities in group 1 included periventricular leukomalacia (68%), periventricular and intraventricular hemorrhage sequelae (15%), and lateral ventriculomegaly (22%). Volumes of total cerebral tissue, white and gray matter, cerebellum, cerebellar gray matter, globus pallidus, and corpus callosum were significantly reduced in group 1 compared with group 2. Positive correlations were found between total cerebral white matter and cerebellar volumes with motor function scores in CP patients. Volumetric neuroimaging reveals more extensive and complex brain involvement in premature children with CP than previously assumed. VolBrain may offer a practical and objective method for monitoring disease progression in clinical settings.
- 6 February 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 178, 26-31
Exploring the Interictal Neuropsychological Burden of Pediatric Migraine
- 6 February 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 178, 26-31
Exploring the Interictal Neuropsychological Burden of Pediatric Migraine